We are on a mission to improve the lives of those living with addiction and to have a broad, positive impact on society.

Together, we can bring psilocybin to the market to empower those who currently don’t have any other assuring options. 

 

Psychedelic medicines show promise to treat substance abuse, addictions, and alcoholism, as demonstrated through clinical studies.

 

Why B.More?

B.More is named after Brett Moore, who died of a drug overdose 50 years ago and was the brother of our co-founder, Claudia Turnbull.  To keep his name alive and help others suffering from addiction disorders, B.More came into being. 

 

B.More is a 501(c)(3) non-profit lifescience company studying psilocybin, a classic psychedelic, to treat patients suffering from Alcohol Use Disorder (AUD) and who may have been unsuccessful with more traditional drug and treatment programs.

 

Brett Moore

The Leading Team

Facing a worldwide problem as big as alcoholism and addiction requires a committed team of experts. 

B.More’s foundation is established upon collaborations with leading institutions, renowned key researchers in AUD and addiction, a leadership team, and scientific advisors steeped in experience to deliver value in breakthrough treatments to this overlooked population.

carey-turnbull-

Carey Turnbull

Founder and CEO

Since 2010 Mr. Turnbull has worked in commercial early-stage drug development for half a dozen companies variously as an investor, founder, and CEO. 

He is on the advisory board of the NYU School of Medicine Department of Psychiatry Psychedelic Research Group, for the Psilocybin Alcohol Use Disorder study, and has assisted in the founding of Yale University’s extensive psilocybin research program. Mr. Turnbull is a member of the board of two Foundations: Heffter Research Institute and Usona Institute, both of which promote research on psychedelic plants and drugs at leading University research departments.

Bonelle-Jeanne

Judy Ashworth, MD

Clinical & Regulatory Strategy

20+ years Analgesic & CNS Drug Development

Bonelle-Jeanne

Jeanne Bonelle

CMC, QA

40+ years Quality Assurance & CMC Development

Bonelle-Jeanne

Marion Coe, PhD

Clinical Scientist

10+ years Clinical Development of CNS Drugs

Bonelle-Jeanne

Shayne Gad, PhD, DABT

Pharmacology & Toxicology

40+ years Toxicology & Pharmacology

Bonelle-Jeanne

Tom Huijbers

Regulatory Affairs, R&D

20+ years Regulatory Pharmaceutical Strategist

Bonelle-Jeanne

Ryan Lanier, PhD

Clinical Scientist

20+ years Pre-Clinical & Clinical Development of CNS Drugs

Bonelle-Jeanne

Stephan Loose, MBA

Business Development

15+ years Pharmaceutical Commercialization & Business Development

Bonelle-Jeanne

Kay Monroe

Program Manager, AUD

20+ years Pharmaceutical Project Management

Bonelle-Jeanne

Amy Poshusta, PhD

Non-clinical Development

20+ years Pharmaceutical Drug Development

Scientific Advisors

Bonelle-Jeanne

Professor, Department of Psychiatry, NYU Grossman School of Medicine, Addiction & Social Anxiety Disorders

Michael Bogenschutz, MD

NYU Langone’s Department of Psychiatry

NYU_Langone
Bonelle-Jeanne

Vice President, Research, Health Policy, and Abuse Liability, Pinney Associates

Adjunct Professor, Behavioral Biology, Medical School’s Department of Psychiatry and Behavioral Sciences

Jack Henningfield, PhD

Pinney Associates
Bonelle-Jeanne

Research Assistant Professor, Department of Psychiatry at NYU Grossman School of Medicine

NYU Clinical Team with Dr Bogenschutz

Sarah E. Mennenga, PhD

NYU Langone’s Department of Psychiatry

NYU Langone

Clinical Team,
NYU Alcohol Use Disorder Study

Bonelle-Jeanne

Michael Bogenschutz, MD

Lead Investigator

NYU_Langone
Bonelle-Jeanne

Sarah E. Mennenga, PhD

Research Assistant Professor

CSP
Bonelle-Jeanne

Christina Marini, MPH

Clinical Research Coordinator

Bonelle-Jeanne

Nicole Northover, MS

Research Data Associate

Bonelle-Jeanne

Kelley O’Donnell, MD, PhD

Research Assistant Professor

Bonelle-Jeanne

Lindsey Owens, MA

Senior Clinical Research Coordinator

Bonelle-Jeanne

Samantha Podrebarac, MA, MSc

Assistant Research Scientist

Bonelle-Jeanne

Dan Roberts, MD

Therapist Trainer & Supervisor

Board of Directors

Bonelle-Jeanne

Founder, Pennant Investors, LLC

Founder, The Fournier Family Foundation

Alan Fournier

Bonelle-Jeanne

30 years, biopharmaceutical

Former co-founder
Savant HWP

Founder & Director MindMed

Stephen Hurst, JD

Bonelle-Jeanne

AMFT, M.A. Existential-Phenomenological Counseling Psychology

Executive Director, Riverstyx Foundation

T. Cody Swift

Bonelle-Jeanne

Advisory Board Member, NYU School of Medicine Department of Psychiatry Psychedelic Research Group, for the Psilocybin Alcohol Use Disorder study

Board Member, Heffter Research Institute

Board Member, Usona Institute

Founder & CEO, Ceruvia Lifesciences

Co-founder & CEO, B.More

Carey Turnbull

Bonelle-Jeanne

Investigator, Johns Hopkins Center for Psychedelic and Consciousness Research

Board Member, Heffter Research Institute

Board Member, Ceruvia Lifesciences

Board of Trustees, College of the Atlantic

Co-founder, B.More

Claudia Turnbull

Partners & Collaborators

Emmes logo

Emmes is a global, full-service clinical research organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation.

Founded in 1977, Emmes has conducted over 2000 clinical studies across a broad range of therapeutic areas, with significant expertise in neurology and the management of studies using schedule 1 drugs. Emmes manages B.More’s Phase 2 AUD study with site support, enrollment, statistical programming, data management and site management/monitoring, and analysis.

Usona Institute is a non-profit medical research organization dedicated to supporting and conducting pre-clinical and clinical research to understand further the therapeutic effects of psilocybin and other consciousness-expanding medicines. Their focus is on alleviating depression in people whose current medical treatments fall short in offering relief and a better quality of life.

Usona has manufactured pharmaceutical-grade psilocybin and is currently conducting the necessary comprehensive pre-clinical toxicology work for prescription medication, enabling B.More’s FDA clinical trials.

Usona_logo
Heffter

The Heffter Research Institute promotes the highest-quality scientific research with classic hallucinogens and related compounds (sometimes called psychedelics) to better understand how the mind improves the human condition and alleviates suffering.

B.More seeks to take academic research Heffter has been instrumental in developing at elite universities and pivot it into prescription medication development trials required by FDA.

New York University (NYU) School of Medicine, one of the nation’s premier academic medical centers, has newly created the NYU Langone Center for Psychedelic Medicine, which conducts trials for B.More focusing on substance abuse disorder research.

NYU_Langone

Download Our Informative Presentation Here:

Funding Psilocybin to Treat Alcohol Use Disorder